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The Korean Diabetes Association (KDA) recently updated the Clinical Practice 
Guidelines on antihyperglycemic agent therapy for adult patients with type 2 
diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents 
(OHAs), general recommendations were not changed from those of the 2015 KDA 
guidelines. The Committee on Clinical Practice Guidelines of the KDA has ex-
tensively reviewed and discussed the results of meta-analyses and systematic 
reviews of effectiveness and safety of OHAs and many clinical trials on Korean 
patients with T2DM for the update of guidelines. All OHAs were effective when 
added to metformin or metformin and sulfonylurea, although the effects of each 
agent on body weight and hypoglycemia were different. Therefore, selection of a 
second agent as a metformin add-on therapy or third agent as a metformin and 
sulfonylurea add-on therapy should be based on the patient’s clinical character-
istics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, 
effect on body weight, patient preference, and combined comorbidity. In this re-
view, we address the results of meta-analyses and systematic reviews, comparing 
the effectiveness and safety among OHAs. It will help to choose the appropriate 
drug for an individual patient with T2DM.
Keywords: Diabetes mellitus, type 2; Efficacy; Oral hypoglycemic agents; Practice 
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INTRODUCTION
The Korean Diabetes Association (KDA) has stated that 
the prevalence of diabetes among adults 30 years or old-
er was about 13.7% in 2014 [1]. Good glycemic control is 
well known to be the best way to prevent chronic com-
plications of diabetes [2], but the control rate of glyce-
mia among those with diagnosed diabetes is only 23.3% 
for a target goal of glycosylated hemoglobin (HbA1c) 
< 6.5% or 43.5% for < 7.0% [1,3]. Because about 80% of 
people with diabetes are treated with oral hypoglycemic 
agents (OHAs) [1,3], it is very important to establish ap-
propriate guidelines for the selection of OHAs. More-
over, most OHAs were developed in Western countries, 
so the efficacy and safety data of OHAs were provided 
from the clinical studies performed on Caucasians. The 
pharmacodynamics and pharmacokinetics of specific 
OHAs can be different among ethnicities. Therefore, it 
is very important to get specifically Korean data. Fortu-
nately, many clinical trials on Korean patients with di-
abetes have been conducted, and the results have been 
published in the past few years. For this 2017 position 
statement regarding pharmacological therapies for 
non-pregnant adult patients with type 2 diabetes mel-
litus (T2DM), extensive review of scientific evidence, in-
cluding the results of clinical trials of OHAs for Koreans 
was performed by the Committee on Clinical Practice 
Guidelines of the KDA. In this review, we describe the 
results of systematic reviews and the considerations 
during the process and propose appropriate combina-
tion therapy of OHAs for Korean patients with T2DM. 
RECOMMENDATIONS 
Principles of treatment with antihyperglycemic 
agents
1.  Metformin is the preferred initial oral antihypergly-
cemic agent [A].
2.  If metformin is contraindicated or intolerable as the 
initial treatment, then another class of antihypergly-
cemic agent can be used, depending on the clinical 
situation [E].
3.  If monotherapy fails to achieve the glycemic goal, then 
combination therapy using a second agent with a dif-
ferent mechanism of action should be initiated [A].
4.  Dual combination therapy can be used as the initial 
management strategy, depending on the patient [B].
5.  Although the maximal dosage of a single oral agent 
may be prescribed, early initiation of combination 
therapy is suitable after considering the glucose-low-
ering efficacy and side-effects of the drug [B].
6.  When selecting a class of antihyperglycemic agents 
for combination therapy, the glucose-lowering ef-
ficacy, risk of hypoglycemia, body weight gain, and 
cardiovascular benefits associated with the drugs are 
preferentially considered [E].
7.  The different mechanisms of action, drug interac-
tions, and patient preferences for combination ther-
apy with more than two classes of antihyperglycemic 
agents should be considered [C].
WHAT IS THE BEST DRUG AS ADD-ON THERA-
PY TO METFORMIN?
There are six major classes of antidiabetic agents that 
can be combined with metformin. They are sulfonylurea 
(SU), thiazolidinediones (TZDs), dipeptidyl peptidase-4 
inhibitors (DPP4i), sodium-glucose cotransporter-2 in-
hibitors (SGLT2i), glucagon-like peptide-1 receptor ag-
onists, and insulin. The American Diabetes Association 
does not prioritize any specific medication and recom-
mends physicians to choose one based on their effica-
cy, hypoglycemic risk, weight effects, side-effects, and 
cost [4]. However, the American Association of Clinical 
Endocrinologists recommended the SGLT2i first, fol-
lowed by DPP4i, TZD, α-glucosidase inhibitors, and SU 
among the OHAs, mainly based on the weight-reducing 
effect [5]. In this paper, we provide a comparative review 
among the OHAs based on meta-analyses and suggest 
a guide to select one as a first-combination medication 
with metformin. 
Comparison of SU and DPP4i as an add-on therapy 
to metformin 
Several meta-analyses compared SU and DPP4i as an 
add-on therapy to metformin [6-11]. DPP4i lowered 
HbA1c levels to a similar extent [6,7] or slightly less 
(HbA1c difference 0.08% to 0.21%) [8,9,11] compared to 
SU when added to metformin (Table 1). A meta-analy-
sis comparing DPP4i with SU as an add-on therapy to 
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metformin showed a significantly greater reduction in 
HbA1c from baseline to 12 weeks with SU versus DPP4i 
(mean difference, 0.21%) but no significant difference 
at 52 and 104 weeks [7]. As we expected, DPP4i was as-
sociated with a lower risk of hypoglycemia (odds ratio 
[OR], 0.12) and weight gain (–0.58 kg) compared to SU. 
In terms of cardiovascular (CV) outcome, there were no 
significant differences between DPP4i and SU for CV 
mortality, all-cause mortality, serious adverse events, or 
myocardial infarction, but DPP4i and metformin exhib-
ited a lower risk of stroke compared with a combination 
of SU and metformin (OR, 0.47; 95% confidence interval 
[CI], 0.23 to 0.95) in a meta-analysis of 301 randomized 
clinical trials involving 118,094 patients published in 
JAMA in 2016 [8]. In a cohort study of 349,476 patients 
with T2DM, using the Korean National Health Insur-
ance Service (NHIS) claims database, however, treatment 
with SU + metformin was associated with increased to-
tal cardiovascular disease (CVD) (hazard ratio [HR], 1.20; 
95% CI, 1.09 to 1.32), myocardial infarction (HR, 1.41; 95% 
CI, 1.04 to 1.91), and ischemic stroke risks (HR, 1.51; 95% 
CI, 1.28 to 1.79) compared with a DPP4i + metformin 
regimen [12]. Because there is no randomized controlled 
prospective study for CV outcomes for SU, and all possi-
ble confounders could not be adjusted in observational 
studies, these results should be interpreted with cau-
tion. However, DPP4i is at least not inferior to SU in 
terms of efficacy and superior in terms of safety. 
Table 1. Summary of meta-analyses reviewed for comparison of sulfonylurea and DPP-4 inhibitor as an add-on therapy to 
metformin 
Study Included trials (n) Results
Palmer et al.
 (2016) [8] 
301 RCTs comparing 2 
glucose-lowering drug 
classes for treatment of 
T2DM for 24 weeks’ or 
longer duration
No significant differences in the associations between any of 9 available 
classes of glucose-lowering drugs (alone or in combination) and the risk of 
cardiovascular or all-cause mortality 
All drugs were effective when added to metformin. 
Mishriky et al.
 (2015) [7]
16 RCTs comparing 
DPP4i to SU as add-on 
therapy to metformin 
A significantly greater reduction in HbA1c from baseline to 12 weeks with  
SU vs. DPP4i (MD, 0.21%; 95% CI, 0.06–0.35)
No significant difference at 52 and 104 weeks (MD, 0.06%; 95% CI, 0.03–0.15; 
and MD, 0.02%; 95% CI, 0.13–0.18, respectively)
SU was associated with weight gain and DPP4i with weight loss at all  
time-points. 
The incidence of hypoglycemia at 12, 52, and 104 weeks was significantly  
greater with SU (20%, 24%, and 27% respectively) compared to DPP4i  
(6%, 3%, and 4% respectively). 
Zhou et al.
 (2016) [9] 
14 RCTS comparing  
DPP4i to SU (5,480 
patients randomised to 
DPP4i and 5,214 patients 
randomised to SU)
Compared with SU, DPP4i were associated with a smaller decline in HbA1c  
(WMD, weighted mean differences, 0.08%; 95% CI, 0.03–0.14; p = 0.001),  
and resulted in weight loss of 1.945 kg (95% CI, –2.237 to –1.653; p < 0.0001). 
The effect of DPP4i lowering FPG was inferior to that of SU (WMD, 0.268 
mmol/L; 95% CI, 0.151–0.385; p < 0.0001), and similar in reducing PPG  
(WMD, 0.084 mmol/L; 95% CI, –0.701 to 0.869; p = 0.833). 
DPP4i had a favorable insulin resistance and low risk for AE and  
hypoglycemia.
Foroutan et al.
 (2016) [10]
10 RCTs comparing 
DPP4i to SU as add-on 
therapy to metformin 
(10,139 subjects)
DPP4i compared to SU produced a non-significant difference in HbA1c% 
change whereas a significant decrease in the rate of hypoglycemic events  
was observed in favor of DPP4i. 
DPP4i was associated with significant weight loss (2.2 kg) compared to SU.
RCT, randomized controlled trial; T2DM, type 2 diabetes mellitus; DPP4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; 
MD, mean difference; CI, confidence interval; HbA1c, glycosylated hemoglobin; WMD, weighed mean difference; FPG, fasting 
plasma glucose; PPG, postprandial glucose; AE, adverse events. 
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Comparison of SU and SGLT2i as an add-on therapy 
to metformin
Two meta-analyses showed that SGLT2i as an add-on 
therapy to metformin lowered HbA1c levels more (0.15%) 
than SU did (Table 2) [6,13-16]. In addition, SGLT2i was 
associated with a lower risk of hypoglycemia and less 
body weight gain [6,8,13]. Because these analyses includ-
ed only three studies, and differences in efficacy among 
SGLT2i results were reported [17], we need to wait for 
further studies.
From pooled data from four empagliflozin phase 
III trials, adjusted mean differences versus placebo in 
change from baseline in HbA1c were −0.61% (baseline, 
7.91%) and −0.75% (baseline, 7.94%) and in weight were 
−1.4 kg (baseline, 70.3 kg) and −1.5 kg (baseline, 72.1 kg) 
with empagliflozin 10 and 25 mg, respectively, when 
combined with metformin in Asian patients with T2DM 
[18]. These results were consistent with previous em-
pagliflozin phase III trials in which at week 24, adjusted 
mean ± SE changes from baseline in HbA1c were −0.70% 
± 0.05% with empagliflozin 10 mg, and −0.77% ± 0.05% 
with empagliflozin 25 mg [19]. In terms of ipragliflozin 
and metformin combination therapy in Korean patients 
with T2DM inadequately controlled with metformin, 
adjusted mean differences versus placebo in change 
from baseline in HbA1c were −0.60% (baseline, 7.67%) 
and in weight were −1.53 kg (baseline, 68.12 kg) with ip-
ragliflozin [20]. These results suggested that the efficacy 
of SGLT2i in Korean patients with T2DM as an add-on 
therapy to metformin would be similar to Caucasian 
populations.  
 
Comparison of DPP4i and SGLT2i as an add-on ther-
apy to metformin 
A meta-analysis of 4 clinical studies showed that SGLT2i 
as an add-on therapy to metformin lowered HbA1c lev-
els more (0.17%) and body weight much more than DP-
P4i (Table 3) [13,21-24]. In a meta-analysis published in 
JAMA in 2016, the rate of treatment failure was signifi-
cantly lower with SGLT2i (OR, 0.68; 95% CI, 0.48 to 0.96) 
and higher with DPP4i (OR, 1.37; 95% CI, 1.07 to 1.76) 
than with SU [8]. In addition, both DPP4i and SGLT2i 
were associated with a lower risk of hypoglycemia com-
pared to SU, and the ORs of both drugs were similar to 
0.12 [19]. 
The CV safety of DPP4i has been demonstrated 
through the Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients with Diabetes Mellitus–
Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 
53), the Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE), and 
the Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin (TECOS) trials [25-27]. However, these trials 
failed to show the CV benefits. In contrast, in the Car-
diovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients (EMPA-REG) Outcome trial, patients 
who received empagliflozin rather than a placebo had 
lower rates of primary composite CV outcome (10.5% vs. 
12.1% in the placebo group; 14% relative risk reduction), 
death from CV causes (3.7%, vs. 5.9%, respectively; 38% 
relative risk reduction), hospitalization for heart failure 
(2.7% and 4.1%, respectively; 35% relative risk reduction), 
and death from any cause (5.7% and 8.3%, respectively; 
32% relative risk reduction) [28]. Moreover, empaglifloz-
Table 2. Between-group differences in the change in HbA1c for comparison of SU and SGLT2i as an add-on therapy to met-
formin [13]
Intervention Trials Duration, wk
No. of 
patients
HbA1c
SGLT2i
HbA1c
control
Change in HbA1c 
(mean difference)
Metformin + 
SGLT2i vs. Met-
formin + SU
Cefalu et al. (2013) [14] 104 1,452 7.8 7.8 –0.19 (–0.29 to –0.09)
Nauck et al. (2011) [15] 208 814 7.7 7.7 –0.30 (–0.79 to 0.19)
Ridderstrale et al. (2014) [16] 104 1,549 7.9 7.9 –0.11 (–0.19 to –0.03)
Total –0.15 (–0.21 to –0.08)
HbA1c, glycosylated hemoglobin; SU, sulfonylurea; SGLT2i, sodium-glucose cotransporter-2 inhibitor.
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in was associated with slower progression of kidney dis-
ease and lower rates of clinically relevant renal events 
[29]. In subsequent the Canagliflozin Cardiovascular 
Assessment Study (CANVAS) and CANVAS–Renal tri-
als, canagliflozin was also associated with lower rates of 
CVD and renal outcome [30]. 
From these results, it appears that SGLT2i can be 
superior to DPP4i. However, there are a few things to 
consider before deciding which drug is better. First, ad-
verse reactions of SGLT2i such as urogenital infection, 
euglycemic diabetic ketoacidosis, or dehydration may 
limit the use of SGLT2i. Second, DPP4i have been re-
ported to be more effective in lowering blood glucose 
levels in Asians, including Koreans, than in Cauca-
sian [31]. A meta-analysis revealed that DPP4i lowered 
HbA1c to a greater extent in studies with ≥ 50% of Asian 
participants (weighted mean difference [WMD], −0.92%; 
95% CI, −1.03 to −0.82) than in studies with < 50% Asian 
participants (WMD, −0.65%; 95% CI, −0.69 to −0.60). The 
between-group difference was −0.26% (95% CI, −0.36 
to −0.17; p < 0.001) [11]. In trials with oral combination 
therapy, HbA1c decreased by 0.66% in the non-Asian 
dominant studies, whereas it decreased by 0.85% in 
the Asian-dominant studies. In fact, in clinical studies 
conducted in Korea, the HbA1c-lowering effect of DP-
P4i was 0.8% to 1.2% after 24 weeks of treatment with 
around 8% of baseline HbA1c [32-34]. These results are 
comparable to the efficacy of the SGLT2i [20].
Therefore, it is difficult to give a comprehensive an-
swer about whether SGLT2i or DPP4i should be prefera-
ble in combination therapy with metformin. The choice 
of an adequate drug should be decided in consideration 
of the individual characteristics of the patient and the 
response to the drug.
Comparison of TZD and SU or DPP4i as an add-on 
therapy to metformin 
A meta-analysis showed that TZD lowered HbA1c levels 
to similarly to SU and slightly more (0.12%) than DP-
P4i when added to metformin [6]. TZD significantly in-
creased body weight compared to SU and DPP4i [6]. This 
meta-analysis included only four randomized clinical 
trials and 674 participants, so the strength of evidence 
was moderate. In addition, as previously commented, it 
should be considered that the glucose-lowering efficacy 
of DPP4i can be higher in Asians than in Caucasians. In 
the study comparing the efficacy of vildagliptin (50 mg 
twice daily) to that of pioglitazone (15 mg once daily) as 
an add-on treatment to metformin in Korean patients 
with T2DM, the efficacy of vildagliptin to lower the 
HbA1c level was not inferior to that of pioglitazone, and 
vildagliptin had beneficial effects on postprandial glu-
cose levels compared to pioglitazone [35]. On the other 
hand, in the study comparing the efficacy of lobeg-
litazone and pioglitazone as add-ons to metformin, 
both of them decreased HbA1c by 0.74% at week 24 
[36]. Therefore, the efficacy difference between DPP4i 
and TZD might be less significant in Koreans.
 In the PROspective pioglitAzone Clinical Trial In 
macroVascular Events (PROactive Study), pioglitazone 
Table 3. Between-group differences in the change in HbA1c for comparison of DPP4i and SGLT2i as an add-on therapy to 
metformin [13]
Intervention Trials
Duration, 
wk
No. 
of patients
HbA1c
SGLT2i
HbA1c
control
Change of HbA1c 
(mean difference)
Metformin + SGLT2i 
vs. Metformin + 
DPP4i
Lavalle-Gonzalez et 
al. (2013) [21]
26 1,284 7.9 7.9 –0.12 (–0.23 to –0.01)
Rosenstock et al. 
(2012) [22]
12 451 7.7 7.6 –0.18 (–0.40 to 0.04)
Rosenstock et al. 
(2015) [23]
24 534 8.9 9.0 –0.32 (–0.53 to –0.11)
DeFronzo et al. 
(2015) [24]
52 899 8.0 8.0 –0.16 (–0.33 to 0.01)
HbA1c, glycosylated hemoglobin; DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor. 
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reduced the composite of all-cause mortality, non-fa-
tal myocardial infarction, and stroke in patients with 
T2DM who have a high risk of macrovascular events [37]. 
In addition, in a cohort study of 349,476 patients with 
T2DM, using the Korean NHIS claims database, treat-
ment with pioglitazone + metformin was associated 
with decreased total CVD (HR, 0.89; 95% CI, 0.81 to 0.99), 
ischemic stroke risks (HR, 0.81; 95% CI, 0.67 to 0.99), and 
increased heart failure risks (HR, 4.81; 95% CI, 3.53 to 
6.56) compared with a DPP4i + metformin combination 
[12]. It has been reported that TZDs have long-term ben-
efits in glycemic control by augmenting insulin sensi-
tivity and preserving β-cell function [38-40]. In the study 
that compared the efficacy of TZDs to other oral glu-
cose-lowering medications in maintaining long-term 
glycemic control in T2DM, the cumulative incidence of 
monotherapy failure at 5 years was 15% with rosiglita-
zone, 21% with metformin, and 34% with glyburide [38]. 
Therefore, it is difficult to say that either DPP4i or TZD 
is superior, and appropriate drugs should be selected af-
ter consideration of individual status. 
TRIPLE ORAL AGENT COMBINATION THERAPY
Five meta-analyses were performed to evaluate the 
comparative effectiveness and safety of triple combina-
tion therapy (drugs added to metformin + SU) (Table 4) 
[8,41-44]. The addition of a third drug to metformin + 
SU therapy was statistically and clinically more effective 
at reducing HbA1c than dual therapy with metformin 
+ SU. In these analyses, the HbA1c-lowering effect was 
consistently better when combined with TZD (–0.93%) 
and SGLT2i (–0.86%) than with DPP4i (–0.68%) or acar-
bose (–0.60%). When triple therapies are compared with 
each other; however, there are no statistically significant 
differences with regard to change in HbA1c for any of 
the comparisons. In a network meta-analysis including 
20 randomized controlled trials, canagliflozin and TZDs 
reduced HbA1c by ~1% (range, 0.98% to 1.2%), where-
as acarbose, dapagliflozin, empagliflozin, and DPP4i 
reduced HbA1c by 0.60% to 0.76% when compared to 
placebo/control [44]. Interestingly, a triple combination 
of metformin + TZD + DPP4i showed no improvement 
in HbA1c compared to metformin + SU [41]. In terms of 
weight, as we can expect, the SGLT2i was associated with 
significant weight loss, and the TZDs and DPP4i result-
ed in significant weight gain compared with placebo/
control. In terms of hypoglycemia, although the results 
are different among the analyses, TZDs as add-on thera-
py to metformin + SU were associated with significantly 
higher rates of hypoglycemia [8,44]. It seems there are 
no statistically significant differences in the risks of hy-
poglycemia among most triple therapies [41]. In terms 
of CV safety, there was no evidence of significantly dif-
ferent associations with CV mortality, all-cause mortal-
ity, or serious adverse events between any of the drug 
classes given as triple therapy [8]. From these analyses, 
the combination of metformin + SU + TZD is the best in 
lowering HbA1c, but it is the worst in weight gain and 
hypoglycemia. The combination of metformin + SU + 
SGLT2i is the second-best in lowering HbA1c, but it is 
the best in weight loss. The combination of metformin 
+ SU + DPP4i is relatively weak in lowering HbA1c com-
pared to metformin + SU + SGLT2i or metformin + SU 
+ TZD. Therefore, SGLT2i is a reasonable option as a 
third agent added to metformin + SU. At this point, we 
have to consider that the efficacy of DPP4i can be higher 
in Asians. Actually, the addition of gemigliptin signifi-
cantly reduced HbA1c levels (0.87% at week 24) com-
pared with placebo in 219 Korean patients inadequately 
controlled with metformin and glimepiride [45]. In the 
other study, the addition of vildagliptin to metformin 
and SU decreased the adjusted mean HbA1c levels by 
1.19% at week 24 [32], and this reduction seems to be 
comparable to that of TZD or SGLT2i.
Because there were only limited data about the com-
parison of other triple combination therapies other 
than the addition of a third drug to metformin + SU, the 
preceding descriptions about triple combination thera-
py need to be interpreted with care. 
CONCLUSIONS
Both in metformin add-on and in metformin + SU add-
on, SGLT2i and TZD showed more efficacy than DP-
P4i or acarbose, but the actual difference was as small 
as 0.1% to 0.2% of HbA1c. Although the difference is 
statistically significant, it does not seem to be clinical-
ly meaningful because usually the difference in HbA1c 
of ≥ 0.3% is regarded as meaningful. In addition, dif-
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Table 4. Summary of meta-analyses reviewed for comparison of triple oral agent combination therapy
Study Included trials (n) Results
Palmer et al. 
(2016) [8]
301 RCTs comparing 2  
glucose-lowering drug 
classes for treatment of 
T2DM for 24 weeks’ or 
longer duration
No significant differences in the associations between any of 9 available classes 
of glucose-lowering drugs (alone or in combination) and the risk of  
cardiovascular or all-cause mortality 
All drugs were effective when added to metformin. 
Mearns et al. 
(2015) [44]
 20 RCTs evaluating 13 
antihyperglycaemic 
agents in adults with 
T2DM experiencing poor 
glycemic control despite 
optimized metformin 
and SU therapy 
Compared with placebo/control, all antihyperglycemic agents reduced HbA1c 
levels, albeit by differing magnitudes (0.6% for acarbose to 1.20%  
for liraglutide) 
SGLT2i reduced weight (1.43–2.07 kg), whereas TZDs, glargine and sitagliptin 
caused weight gain (1.48–3.62 kg) compared with placebo/control. 
SGLT2i, rosiglitazone and liraglutide decreased SBP compared with placebo/
control, pioglitazone, glargine and sitagliptin (2.41–8.88 mmHg)
Glargine, TZDs, liraglutide, sitagliptin, and canagliflozin increased  
hypoglycemia risk compared with placebo/control (relative risk, 1.92–7.47), 
while glargine and rosiglitazone increased hypoglycemia compared with 
most antihyperglycemic agents (relative risk, 2.81–7.47). 
Canagliflozin increased the risk of genital tract infection by 3.9-fold compared 
with placebo/control.
Downes et al. 
(2015) [41]
27 RCTs comparing  
metformin + SU dual 
therapy to other triple 
therapy combinations
For HbA1c reduction, all triple therapies were statistically superior to  
metformin + SU dual therapy, except for metformin + TZD + DPP4i.  
None of the triple therapy combinations demonstrated differences in HbA1c 
compared with other triple therapies. 
Metformin + SU + SGLT2i and metformin + SU + GLP-1RA resulted in  
significantly lower body weight than metformin + SU + DPP4i, metformin + 
SU + insulin and metformin + SU + TZDs; metformin + SU + DPP4i resulted  
in significantly lower body weight than metformin + SU + insulin and  
metformin + SU + TZD. 
Metformin + SU + insulin, metformin + SU + TZD and metformin + SU +  
DPP4i increased the odds of hypoglycaemia when compared to metformin + 
SU. Metformin + SU + GLP-1RA reduced the odds of hypoglycemia compared 
to metformin + SU + insulin. 
Lee et al. (2016) 
[42]
40 RCTS comparing dual 
therapy to any triple 
combinations 
(15,182 participants)
Compared with none/placebo added to dual therapy, triple combination  
therapy resulted in significant additional mean reductions in HbA1c from 
–0.56% (DPP4i) to –0.94% (TZDs). 
Insulin, TZD and SU were associated with less favourable weight change and  
GLP-1RA and SGLT2i were associated with more favourable weight change  
when compared with none/placebo added to dual therapy. 
Compared with none/placebo added to dual therapy, the odds of hypoglycemia  
were higher for DPP4i (1.95), SGLT2i (2.27), GLP-1RA (2.61), TZD (2.83), and 
insulin (5.94). 
Lozano-Ortega 
et al. (2016) [43]
30 RCTs comparing 
SGLT2i to other drugs as 
add-on therapy to  
metformin and SU
The mean change (%) in HbA1c levels compared to placebo was –0.86 for  
SGLT2i, –0.68 for DPP4i, –0.93 for TZDs, and –1.07 for GLP-1RA, respectively. 
Only SGLT2i and GLP-1RA led to a weight loss (–1.71 and –1.14 kg, respectively) 
and decrease in SBP (–3.73 and –2.90 mmHg, respectively), while all other 
treatments showed either an increase or no changes in weight or SBP.
RCT, randomized controlled trial; T2DM, type 2 diabetes mellitus; SU, sulfonylurea; HbA1c, glycosylated hemoglobin; SGLT2i, 
sodium-glucose cotransporter-2 inhibitor; TZD, thiazolidinedione; SBP, systolic blood pressure; DPP4i, dipeptidyl peptidase-4 
inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist.
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ferences in efficacy or safety of each drug even in the 
same class have been reported, and the response to indi-
vidual drugs can be different, depending on ethnicities 
and/or individual characteristics. Therefore, the choice 
of drug requires many aspects of consideration, such as 
patient preferences, patient characteristics, comorbidi-
ty, and drug characteristics, with the goal of reducing 
blood glucose levels and side effects, including weight 
gain and hypoglycemia.
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